Across TCGA pan-cancer cohorts, CCDC96 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CCDC96 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CCDC96 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC96 expression acts as an unfavorable survival marker.
SKCM are the cancer types where CCDC96 Mutation most reproducibly stratifies survival.